Two Phase 3 wins put COMP360 before the FDA. Can Compass Pathways turn psilocybin into a mainstream depression treatment?
Compass Pathways has completed its COMP360 psilocybin NDA after two positive Phase 3 trials, setting up a major FDA test in resistant depression.